Currently held
- Agent 4 — Dip Buyer (Frozen)long2 sh @ $377.35 · stop $347.16+$6.26 unrealized
AMGN
AMGEN IncHealth Careinsider_universeLast close $380.24Sep 13, 2026
Day +0.77%
Everything we've seen
- ?Sep 14, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 14, 3:20 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 14, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ·Sep 14, 3:19 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 3:19 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 3:19 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 3:19 PMstreamnews
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]
- ·Sep 14, 3:04 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 3:04 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 3:04 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 3:04 PMstreamnews
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]
- ·Sep 14, 2:49 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 2:49 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:49 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 2:49 PMstreamnews
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]
- ·Sep 14, 2:34 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 2:34 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:34 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 2:34 PMstreamnews
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]
- ?Sep 14, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 14, 2:20 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 14, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ·Sep 14, 2:19 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 2:19 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:19 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 2:04 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 2:04 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:04 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 1:49 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 1:49 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:49 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 1:33 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 1:33 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:33 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ?Sep 14, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ?Sep 14, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 14, 1:20 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ·Sep 14, 1:17 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 1:17 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:17 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 1:01 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 1:01 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:01 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 12:46 PMstreamnews
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ·Sep 14, 12:46 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 12:46 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ·Sep 14, 12:31 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 12:31 PMstreamnews
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ?Sep 14, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 14, 12:20 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 14, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ?Sep 14, 11:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ?Sep 14, 11:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 14, 11:21 AMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 14, 10:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 14, 10:21 AMsignalseverity 0.16
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 14, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ❖Sep 14, 9:00 AMnewsvia finnhub
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- ❖Sep 14, 9:00 AMnewsvia finnhub
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the IMDELLTRA® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting.
- ❖Sep 14, 8:45 AMnewsvia finnhub
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
- ❖Sep 14, 7:03 AMnewsvia finnhub
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
- ?Sep 14, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ?Sep 14, 7:00 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 14, 7:00 AMsignalseverity 0.16
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ❖Sep 13, 10:29 AMnewsvia finnhub
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]
- ❖Sep 12, 6:48 AMnewsvia finnhub
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
- ❖Sep 12, 4:49 AMnewsvia finnhub
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ❖Sep 12, 4:15 AMnewsvia finnhub
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
- ✓Sep 11, 6:04 PMdecisionacted
Agent 4 — Dip Buyer (Frozen) — decide: buy
Amgen is a large-cap, diversified biopharmaceutical company with a strong balance sheet, robust free cash flow, and a broad product portfolio (Repatha, Enbrel, Evenity, MariTide in pipeline), making it fundamentally sound. The 15.6% drawdown from the 30-day high has no identifiable company-specific catalyst in the available evidence — no negative headlines, no guidance cuts, and no red-flag disclosures in the 10-Q or 8-K filings. The primary headwind is macro: the 5-year forward inflation rate (T5YIFR) is running 1.8σ above its 24-month trend, pressuring rate-sensitive and high-debt sectors, and Amgen carries notable long-term debt; however, its cash generation capacity and defensive demand profile partially insulate it.
- ?Sep 11, 4:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ?Sep 11, 4:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 11, 4:20 PMsignalseverity 0.16
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 11, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 11, 3:20 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 11, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ❖Sep 11, 3:10 PMnewsvia finnhub
Friday's session: top gainers and losers in the dow jones index
Stay informed about the performance of the dow jones index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
- ❖Sep 11, 3:02 PMnewsvia finnhub
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential
Amgen (NASDAQ:AMGN) executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion. Chief Financial Officer Thomas Dittrich, who recently returne
- ?Sep 11, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 11, 2:21 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 11, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ?Sep 11, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 11, 1:20 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 11, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ❖Sep 11, 12:40 PMnewsvia finnhub
These dow jones stocks are moving in today's session
Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.
- ?Sep 11, 12:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 11, 12:21 PMsignalseverity 0.15
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 11, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ❖Sep 11, 12:05 PMnewsvia finnhub
Amgen Drops 10% on a Trial It Didn't Even Run
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
- ❖Sep 11, 11:49 AMnewsvia finnhub
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
- ❖Sep 11, 11:29 AMnewsvia finnhub
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
- ❖Sep 11, 11:19 AMnewsvia finnhub
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (NYSE:AZN) received a positive boost after their combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial […]
- ❖Sep 11, 9:40 AMnewsvia finnhub
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
- ❖Sep 11, 9:35 AMnewsvia finnhub
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
- ❖Sep 11, 5:37 AMnewsvia finnhub
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
- ❖Sep 10, 5:50 PMnewsvia finnhub
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $382.47, representing a -2.25% change from its previous close.
- ?Sep 10, 4:26 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] Wanted to buy but only $120.83 cash available; close=$391.17.
- ?Sep 10, 4:26 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 10, 4:26 PMsignalseverity 0.14
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 10, 3:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 15 minutes remaining until the forced close, there is very limited runway for continuation even if the setup were otherwise strong. The -2.23% move in AMGN is meaningful and represents real selling pressure, but the critical constraint here is time. At 15 minutes to cutoff, most of the intraday move has already been realized, and late-session dynamics often involve mean reversion or positioning squaring rather than trend extension. The macro context (elevated 5Y5Y inflation forward rate at 1.6σ above trend) is broadly negative for rate-sensitive sectors, which could apply mild pressure to large-cap biotech like AMGN, but this is a weak signal at best — AMGN is not a pure rate-sensitive play. No news headlines are present to explain or sustain the selling. With such little time remaining, the risk/reward of a downside continuation trade is poor: even if directionally correct, there is minimal distance for the +3% profit target to be reached before the 3:45 PM flatten, while the -1.5% stop remains fully at risk. Time remaining is the dominant factor here, pushing continuation probability below 0.5.
- !Sep 10, 3:30 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
With only 15 minutes remaining until the forced close, there is very limited runway for continuation even if the setup were otherwise strong. The -2.23% move in AMGN is meaningful and represents real selling pressure, but the critical constraint here is time. At 15 minutes to cutoff, most of the intraday move has already been realized, and late-session dynamics often involve mean reversion or positioning squaring rather than trend extension. The macro context (elevated 5Y5Y inflation forward rate at 1.6σ above trend) is broadly negative for rate-sensitive sectors, which could apply mild pressure to large-cap biotech like AMGN, but this is a weak signal at best — AMGN is not a pure rate-sensitive play. No news headlines are present to explain or sustain the selling. With such little time remaining, the risk/reward of a downside continuation trade is poor: even if directionally correct, there is minimal distance for the +3% profit target to be reached before the 3:45 PM flatten, while the -1.5% stop remains fully at risk. Time remaining is the dominant factor here, pushing continuation probability below 0.5.
- ❖Sep 10, 3:10 PMnewsvia finnhub
Which dow jones stocks are moving on Thursday?
Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
- ?Sep 10, 1:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is down 2.34% intraday with no attributable headline, suggesting either broad biotech/sector selling pressure or institutional distribution. The macro context shows the 5Y5Y inflation forward (T5YIFR) printing 1.6σ above trend — elevated inflation expectations tend to pressure rate-sensitive and high-multiple sectors, and large-cap biotech like AMGN carries meaningful duration risk in its valuation. With 150 minutes remaining there is ample time for continuation, and the magnitude of the move (~$9 decline) reflects real order flow rather than noise. However, absent a specific catalyst, a move of this size can attract dip buyers in a name with AMGN's defensive characteristics (dividend, buybacks, stable earnings profile), which limits high-conviction continuation. No reversal pattern is evident from available data, and the macro headwind is modest rather than acute. Overall, slight lean toward continuation of the downside move, but this is a low-conviction call — probability just above the trigger threshold.
- !Sep 10, 1:16 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 2.34% intraday with no attributable headline, suggesting either broad biotech/sector selling pressure or institutional distribution. The macro context shows the 5Y5Y inflation forward (T5YIFR) printing 1.6σ above trend — elevated inflation expectations tend to pressure rate-sensitive and high-multiple sectors, and large-cap biotech like AMGN carries meaningful duration risk in its valuation. With 150 minutes remaining there is ample time for continuation, and the magnitude of the move (~$9 decline) reflects real order flow rather than noise. However, absent a specific catalyst, a move of this size can attract dip buyers in a name with AMGN's defensive characteristics (dividend, buybacks, stable earnings profile), which limits high-conviction continuation. No reversal pattern is evident from available data, and the macro headwind is modest rather than acute. Overall, slight lean toward continuation of the downside move, but this is a low-conviction call — probability just above the trigger threshold.
- ❖Sep 10, 12:40 PMnewsvia finnhub
Explore the top gainers and losers within the dow jones index in today's session.
Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Thursday.
- ❖Sep 10, 12:21 PMnewsvia finnhub
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ❖Sep 10, 11:56 AMnewsvia finnhub
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
- ?Sep 10, 11:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is down 2.12% today with no attributable headline, suggesting this is flow/technical-driven selling rather than a news catalyst. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a mild headwind for rate-sensitive sectors including large-cap biotech (higher discount rates pressure growth/biotech valuations). With 255 minutes remaining, there is ample time for continuation. However, the absence of a news catalyst means this could be sector rotation or index-level selling rather than stock-specific conviction, which limits confidence in sustained directional pressure. No reversal signals are evident from the data provided. The move magnitude (just over 2%) is meaningful but not extreme, and without volume data or clear catalyst, this is a borderline read. Slight lean toward continuation given macro rate headwind context and time remaining, but conviction is modest.
- !Sep 10, 11:30 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 2.12% today with no attributable headline, suggesting this is flow/technical-driven selling rather than a news catalyst. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a mild headwind for rate-sensitive sectors including large-cap biotech (higher discount rates pressure growth/biotech valuations). With 255 minutes remaining, there is ample time for continuation. However, the absence of a news catalyst means this could be sector rotation or index-level selling rather than stock-specific conviction, which limits confidence in sustained directional pressure. No reversal signals are evident from the data provided. The move magnitude (just over 2%) is meaningful but not extreme, and without volume data or clear catalyst, this is a borderline read. Slight lean toward continuation given macro rate headwind context and time remaining, but conviction is modest.
- ❖Sep 10, 10:27 AMnewsvia finnhub
Amgen Inc. (AMGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Amgen Inc. (AMGN) Wells Fargo 21st Annual Healthcare Conference September 10, 2026 11:00 AM EDTCompany ParticipantsThomas J.
- ❖Sep 10, 9:52 AMnewsvia finnhub
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
- ❖Sep 10, 8:09 AMnewsvia finnhub
Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More
Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs, setting up a make-or-break inflation report that could seal the Fed's next move. Wall Street analysts are already repositioning across semiconductors, biotech, and energy ahead of the fallout.
- ❖Sep 10, 6:13 AMnewsvia finnhub
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425
HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price target from $445 to $425.
- ❖Sep 10, 5:13 AMnewsvia finnhub
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
Investing.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the second quarter of 2026.
- ❖Sep 10, 2:14 AMnewsvia finnhub
Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade)
Amgen raised full-year 2026 revenue and EPS guidance, signaling improved confidence. Find out why AMGN stock is upgraded to buy.
- ❖Sep 9, 10:32 PMnewsvia finnhub
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes
Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.
- ❖Sep 9, 5:48 PMnewsvia finnhub
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]
- ❖Sep 9, 5:06 PMnewsvia finnhub
Buy the dip; favor U.S. utilities and consumer staples and discretionary: Matrix Asset Advisors CIO
David Katz of Matrix Asset Advisors says it is normal for markets to take a breather after a strong run, suggesting investors buy the dips if the market pulls back 3-5%. He favors U.S. utilities and sees opportunities in consumer staples and discretionary stocks, despite their recent underperformance.
- ❖Sep 9, 4:41 PMnewsvia finnhub
What Eli Lilly Was Telling You While It Rationed Its Own Launches
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
- ?Sep 9, 4:25 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 9, 4:25 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 9, 4:25 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $120.83 cash available; close=$391.17.
- !Sep 9, 4:25 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $16.33 cash available; close=$393.22.
- ❖Sep 9, 4:01 PMnewsvia finnhub
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen, and Thomas Dittrich, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and th
- ❖Sep 9, 2:01 PMnewsvia finnhub
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals
The Imdelltra-Imfinzi combination improved survival and response measures in a 563-patient late-stage lung-cancer trial.
- ❖Sep 9, 12:40 PMnewsvia finnhub
Stay informed with the top movers within the dow jones index on Wednesday.
Stay informed about the performance of the dow jones index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
- ❖Sep 9, 7:11 AMnewsvia finnhub
Stock Market News for Sep 9, 2026
Wall Street ended lower as market participants weighed inflation concerns, rising oil prices and interest-rate expectations.
- ❖Sep 9, 6:10 AMnewsvia finnhub
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.
- ❖Sep 9, 12:01 AMnewsvia finnhub
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’s clinical data webcast.
- ?Sep 8, 4:22 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $16.33 cash available; close=$393.22.
- !Sep 8, 4:22 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $27.98 cash available; close=$395.85.
- ?Sep 8, 4:22 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 8, 4:22 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 8, 1:24 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $27.98 cash available; close=$395.85.
- !Sep 8, 1:24 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $5.80 cash available; close=$396.49.
- ?Sep 8, 1:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 8, 1:24 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 8, 11:25 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- !Sep 8, 11:25 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
- ?Sep 8, 11:25 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $5.80 cash available; close=$396.49.
- !Sep 8, 11:25 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
AMGN is down 11.3% from its 30-day high with no identifiable fundamental catalyst — no guidance cuts, going-concern language, or fraud allegations appear in recent filings, and there are no news headlines driving idiosyncratic negative sentiment. Options flow is notably bullish, with a low P/C ratio of 0.38 and put volume at a -1.87 z-score (well below normal), suggesting the market is not positioning defensively against this name. Health Care (XLV) ranks 3rd of 11 sectors by 30-day relative strength and is outperforming SPY on both 5d and 30d bases, which slightly penalizes the thesis (idiosyncratic dip in an outperforming sector), but the absence of any known company-specific negative driver tempers that concern. Earnings are 55 days away, providing a clean runway for rebound, and VIX at 14.32 (2nd percentile) reflects an exceptionally calm macro environment despite the headwind of a 4.77% 10Y yield.
- ?Sep 4, 6:02 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $437.23 > MA150 $366.88 (+19.2%), MA rising, 2.2% off 52w high, vol 0.44× avg
- ?Sep 4, 6:01 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $437.23 > MA150 $366.88 (+19.2%), MA rising, 2.2% off 52w high, vol 0.44× avg
- ?Sep 3, 6:03 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $444.12 > MA150 $366.24 (+21.3%), MA rising, 0.7% off 52w high, vol 0.81× avg
- ?Sep 3, 6:03 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $444.12 > MA150 $366.24 (+21.3%), MA rising, 0.7% off 52w high, vol 0.81× avg
- ?Sep 2, 6:03 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $442.84 > MA150 $365.57 (+21.1%), MA rising, 0.9% off 52w high, vol 0.69× avg
- ?Sep 2, 6:03 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $442.84 > MA150 $365.57 (+21.1%), MA rising, 0.9% off 52w high, vol 0.69× avg
- ?Sep 1, 6:03 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $438.12 > MA150 $364.90 (+20.1%), MA rising, 2.0% off 52w high, vol 1.46× avg
- ?Sep 1, 6:02 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $438.12 > MA150 $364.90 (+20.1%), MA rising, 2.0% off 52w high, vol 1.46× avg
- ?Aug 31, 6:03 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $429.93 > MA150 $364.32 (+18.0%), MA rising, 3.8% off 52w high, vol 1.31× avg
- ?Aug 31, 6:03 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $429.93 > MA150 $364.32 (+18.0%), MA rising, 3.8% off 52w high, vol 1.31× avg
- ?Aug 28, 6:02 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $432.42 > MA150 $363.78 (+18.9%), MA rising, 3.3% off 52w high, vol 0.67× avg
- ?Aug 28, 6:02 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $432.42 > MA150 $363.78 (+18.9%), MA rising, 3.3% off 52w high, vol 0.67× avg
- !Aug 5, 6:01 PMsignal
Agent 1 — Immutable — insufficient_capital
- !Aug 4, 1:36 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 2.20% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news catalyst. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm: (1) No news catalyst means the move could be isolated flow that has largely completed. (2) The macro context shows 5-year inflation expectations (T5YIE) at 1.5σ below trend — a deflationary tilt that is generally modestly supportive for large-cap defensive biotech like AMGN (lower discount rates), but the reactive sectors cited are Gold/Energy/TIPS, not healthcare/biotech, so macro tailwind is indirect at best. (3) With 130 minutes remaining, there is adequate time for continuation but also adequate time for profit-taking to develop. (4) No reversal signals are evident from the data provided. Overall, the absence of a reason to fade and the meaningful move already in place tilt the read slightly toward continuation, but without a clear catalyst or sector-specific macro driver, confidence is modest.
- !Jul 31, 10:51 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 1.52% today, a moderate move that suggests some selling pressure but not a decisive breakdown. There are no recent headlines to explain the move, which could indicate quiet institutional selling or sector rotation rather than a news-driven catalyst. The macro context (elevated mortgage rates at 6.66%) is not directly relevant to AMGN as a large-cap biotech/pharma name, offering neither tailwind nor headwind here. With 295 minutes remaining (nearly a full session left), there is ample time for the move to continue or reverse. The -1.52% move is below the 2% threshold where momentum signals become more reliable, and without a clear catalyst or sector pressure to sustain selling, the setup is borderline. No reversal pattern is evident, but the lack of news-driven conviction and the move's modest magnitude prevent a higher confidence call. Assigning continuation probability at the threshold — enough to warrant a position per system rules, but without strong conviction.
- !Jul 28, 9:36 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 3.06% intraday with no attributable headline, suggesting institutional flow or possibly a catalyst not yet captured in the news feed (earnings, pipeline update, or analyst action). A move of this magnitude in a large-cap biotech like AMGN reflects real conviction and size. However, several factors temper the continuation probability: (1) No confirming headline or catalyst is visible, making it harder to assess whether the initial buyers have more to add or are done; (2) The macro backdrop shows 10Y inflation expectations (T10YIE) running 1.7σ below trend at 2.21, which is bond-friendly and generally supportive of long-duration assets including high-multiple biotech — this is a mild tailwind; (3) With 370 minutes remaining until the forced close, there is ample time for the move to extend, but also ample time for profit-taking to develop; (4) No evidence of reversal or fade pattern based on the data provided — current price appears to reflect the move rather than a rejection off highs. On balance, this is an ordinary momentum read with mild macro support. The move likely has at least partial continuation given real flow already present, but without a clear catalyst or volume confirmation, high conviction is not warranted. Assigning 0.54 — modest lean toward continuation, sufficient to trigger given the system's bounded risk profile.
- !Jul 6, 10:30 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 3.21% intraday with no headline catalyst identified, suggesting the move is driven by institutional flow or sector rotation rather than a discrete news event. The magnitude (~$12 drop) represents meaningful conviction from sellers. The macro context shows 10Y inflation expectations (T10YIE) printing 1.6σ below trend, which is modestly favorable for long-duration assets and biotech/pharma (which tend to benefit from lower real rates), creating a mild headwind to further downside continuation. However, this macro factor is not strong enough to reverse a 3%+ move on its own. With 315 minutes remaining (a full trading day's worth of intraday time essentially), there is ample runway for continuation if sellers remain in control. No reversal pattern or fade signal is evident from the data provided. Balancing the meaningful downside momentum against the slightly supportive macro backdrop and absence of a news catalyst to sustain selling pressure, a modest continuation probability is warranted — leaning toward continuation but without high conviction.
- !Jul 2, 6:03 PMsignal
options_momentum — insufficient_capital